Medtronic Launches Evolut FX+ TAVR System in India, Offering New Hope for Over 48.7 Million Elderly Women and Millions More

Medtronic Officially Launches Its Supra-annular, Self-expanding Evolut FX+ Transcatheter Aortic Valve Replacement（TAVR）System. The Central Drug Standard Control Organization of the country 6 Approved in the month for the treatment of patients with severe aortic stenosis.

It is believed that, as of 2023 Year, India's population was approximately 14 100 million. According to one estimate, this includes more than 4420 Ten thousand males and over 4870 Ten Thousand 65 Women aged or above.Medtronic has developed Evolut FX+ TAVR System, and considered improving coronary access. Its coronary access window is significantly larger than previous ones. Evolut Valves enhance the potential for catheter-based interventions if patients require future coronary interventions after treatment.

Due to the increasing use by younger patients TAVRInterventional cardiologists are now more focused than ever on lifelong patient management. If TAVR If the patient requires immediate treatment for myocardial infarction or other adverse health events later in life, coronary artery access becomes a critical detail.

Design with Ingenuity: Balancing Durability and Pathway

Evolut FX + System inDesigned with great foresight, fully considering the long-term treatment needs of patients and the convenience of surgical operations.。From the perspective of durability, its inflow tract area is meticulously designed with radial support equivalent to the Evolut™ FX valve. This means that during long - term use, the valve can firmly maintain its shape, withstand the strong pressure generated by cardiac contraction and relaxation, and is not prone to deformation or displacement, laying a solid foundation for the long - term stable operation of the valve.And in the outflow tract portion, it similarly possesses features akin to Evol.The consistent structural strength of the ut™ FX valve ensures that blood can flow smoothly and efficiently out of the heart, reducing blood stagnation at the valve and lowering the risk of thrombosis, thereby ensuring smooth cardiac blood circulation for patients.

Coronary Access Design: A Key Highlight of Evolut FX +The system features three windows, which are four times larger than those in the previous Evolut valve. This allows interventional cardiologists to more easily and precisely guide catheters into the coronary arteries during future coronary interventions, should patients experience adverse health events like myocardial infarction after TAVR treatment. The enlarged access windows significantly enhance the flexibility and accessibility of catheter manipulation. For patients, this means more timely and effective treatment during critical moments, greatly improving the success rate and safety of follow-up procedures.

Clinical Data Demonstrates Strength

Medtronic Evolut FX + System Demonstrates Remarkable Excellence in Clinical Applications. In a significant clinical study, the system exhibited outstanding performance in numerous aspects. Regarding the Effective Orifice Area (EOA) metric, the Evolut FX + System consistently maintains a larger value over the long term. A larger EOA ensures smoother blood flow through the valve during heart pumping, reducing valve resistance and thereby decreasing the heart's workload, allowing it to function more efficiently. The Evolut FX + also performs exceptionally well in reducing transvalvular pressure gradients. A lower transvalvular pressure gradient means less resistance for blood flowing through the valve, enabling the heart to pump blood without excessive contraction, which has a positive and profound impact on improving patients' cardiac function and enhancing their quality of life.

In comparative studies, the Evolut FX+ demonstrated significant advantages over other similar TAVR systems across multiple key clinical endpoints. In terms of all-cause mortality, a critical measure of treatment efficacy, the patient group treated with Evolut FX+ showed lower values. This clearly indicates that using this system for treatment can effectively reduce the risk of death from various causes, providing stronger protection for patients' health. Regarding the incidence of disabling strokes, the Evolut FX+ system also performed exceptionally well, with a significantly lower probability of disabling strokes in patients treated with this system compared to those using other similar products. Disabling strokes impose a heavy burden on patients and their families, and the outstanding performance of the Evolut FX+ system in reducing this risk undoubtedly brings more hope for patient outcomes. Additionally, in terms of heart failure readmission rates, the Evolut FX+ system again showed its superiority, with a significant reduction in patients being readmitted due to heart failure. This fully demonstrates the system's strong capability in improving long-term cardiac function and reducing the risk of disease recurrence.

Globally Recognized, Opening a New Chapter in Treatment

In March 2024, the U.S. Food and Drug Administration (FDA) approved the Evolut FX+ TAVR system, a decision that encompasses symptomatic severe aortic stenosis patients at low, intermediate, high, and extreme risk. In October of the same year, it also successfully received CE mark approval. These two endorsements from leading global healthcare authorities fully demonstrate that the Evolut FX+ system has achieved extremely high standards in terms of safety and efficacy.This means that more patients with aortic stenosis worldwide, regardless of their risk level, will have the opportunity to benefit from this advanced medical technology. It not only provides doctors with a more powerful and reliable treatment tool but also brings hope to patients for regaining a healthy life, opening a new chapter in the global field of cardiovascular disease treatment.

Senior Director of Medtronic Neuroscience and Specialty TherapiesPrateek Tiwari Said in a statement:“Evolut FX+ The launch in India marks a significant step forward in transcatheter valve therapy.“With its enhanced coronary access and proven hemodynamic performance,FX+ Enable doctors to provide confident care——Not only during the initial surgery but throughout the patient's entire life. By bringing this innovation to India, we are advancing Medtronic's mission to alleviate pain, restore health, and extend life, while expanding future-oriented solutions for structural heart disease.